FDA Pulls Evusheld EUA, But AstraZeneca Has Another Antibody in The Wings

The FDA has pulled the Emergency Use Authorization (EUA) for AstraZeneca’s Evusheld (tixagevimab/cilgavimab) because, the agency says, more than 90 percent of the circulating SARS-CoV-2 variants in the U.S. are now resistant to it.
Source: Drug Industry Daily